跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
林 孟穎
助理教授
,
眼科學科
主治醫師
,
衛生福利部雙和醫院
https://orcid.org/0000-0003-1905-4757
電子郵件
b8301038
tmu.edu
tw
,
10208
s.tmu.edu
tw
h-index
111
引文
6
h-指數
按照存儲在普爾(Pure)的出版物數量及斯高帕斯(Scopus)引文計算。
2010
2024
每年研究成果
概覽
指紋
網路
研究成果
(14)
類似的個人檔案
(6)
指紋
查看啟用 Meng-Yin Lin 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
LASIK
100%
Small Incision Lenticule Extraction
96%
Astigmatism
78%
Intraocular Pressure
56%
Astigmatism Correction
52%
Intubation
48%
Nasolacrimal Duct Obstruction
48%
Systematic Review
48%
Keratotomy
48%
Toric Intraocular Lens
48%
Femtosecond Laser-Assisted Cataract Surgery
48%
Meta-Analysis
48%
Combination Therapy
48%
Cohort Analysis
48%
Phacoemulsification
48%
Dry Eye
48%
Disseminated Herpes Zoster
48%
Intraocular Lens Implantation
48%
Quality of Life
48%
Eye Disease
48%
Iridocyclitis
48%
Retinal Nerve Fiber Layer
48%
Proportional Hazards Model
48%
Batimastat
48%
Marimastat
48%
Hazard Ratio
36%
Visual Acuity
26%
Postherpetic Neuralgia
24%
Mixed Model
24%
Symptom
24%
Linear Regression Analysis
18%
Patient-Reported Outcome
16%
Matrix Metalloproteinase Inhibitor
16%
Refractive Error
13%
Best Corrected Visual Acuity
13%
Neurologic Disease
12%
Herpes Zoster Ophthalmicus
12%
Neurological Complication
12%
Elderly Patient
12%
Corneal Topography
9%
Randomized Controlled Trial
9%
Balloon Dilatation
9%
Effect Size
9%
Surgeon
9%
Anterior Chamber of Eyeball
8%
Uveitis
8%
Outcome Assessment
8%
Clinician
8%
Wellbeing
8%
Diagnostic Test
8%
Pharmacology, Toxicology and Pharmaceutical Science
Intubation
48%
Eye Disease
48%
Antilipemic Agent
48%
Statin (Protein)
48%
Dry Eye
48%
Thromboembolism
48%
Obstruction
48%
Iridocyclitis
48%
Aflibercept
48%
Ranibizumab
48%
Marimastat
36%
Brain Ischemia
32%
Acute Heart Infarction
24%
Coronary Artery Disease
24%
Endothelial Cell Growth Factor
24%
Refraction Error
20%
Uveitis
13%
Randomized Controlled Trial
9%
Cohort Study
8%
Disease
8%
Eye Inflammation
6%
Prevalence
6%
Disease Course
6%
Inflammation
6%
Comorbidity
5%
Fibric Acid Derivative
5%